MRNA发财

Moderna MRNA +3.22%  said it was in “active supply discussions” for new orders of its Covid-19 vaccine with the European Union despite a recent press report suggesting that the bloc was close to a virtually exclusive supply deal with Pfizer and BioNTech.

“We are having discussions with Europe to supply Europe for the fall of ’23,” Moderna CEO Stéphane Bancel told Barron’s early Thursday.

A report on Sunday from the Financial Times sent jitters across Wall Street, not only because it suggested that Moderna and other manufacturers would be effectively locked out of the European Covid-19 vaccine market. It also said that the E.U. would buy only 70 million doses per year from Pfizer PFE –0.57%  and BioNTech BNTX –2.25% , far fewer than analysts had expected.